Dr. Paul Frohna is a physician-scientist with over 20 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy.
Before joining ImCheck, Dr. Frohna was Chief Medical Officer at Bioniz Therapeutics, where he led clinical and regulatory affairs functions and was responsible for the operational oversight of the Company's clinical programs in T-cell leukemia and lymphoma as well as autoimmune diseases. Prior to this role, Dr. Frohna was the Vice President of Clinical Development and Translational Medicine at Receptos Inc., where he led the successful Phase 2 trials of ozanimod in multiple sclerosis and inflammatory bowel disease. Prior to Receptos, Paul served as the Chief Medical Officer of ProFibrix, Inc. where he led the successful Raplixa™ clinical program, and previously held senior clinical development positions at Fibrogen and at Genentech where he patented and initially tested the therapeutic approach of B-cell depleting therapy for relapsing and progressive multiple sclerosis. Dr Frohna currently serves as an independent director on the board of Accure Therapeutics, a Barcelona-based, clinical-stage private biotech developing first-in-class neurotherapeutics.
Over the course of his career, Dr. Frohna has built and led departments, including clinical development, translational medicine, clinical pharmacology, drug safety, and regulatory affairs. His leadership has been demonstrated on clinical and project teams responsible for candidate selection, IND filings, Phase I to III clinical trials, and global development partnerships. He has successfully designed and initiated translational and clinical programs for biologics, small molecules, and stem cells, across multiple therapeutic areas including immunology and oncology. He played critical roles in multiple development programs, including Receptos' ozanimod, Fibrogen’s roxadustat and Genentech's Rituxan, Tarceva, and Raptiva programs.
Dr. Frohna received his pharmacy degree from the University of Texas at Austin College of Pharmacy, his PhD in Pharmacology from the University of Pennsylvania School of Medicine, and his MD from Georgetown University School of Medicine.